Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen

被引:20
作者
Aksoy, Evrim Kahramanoglu [1 ]
Sapmaz, Ferdane Pirincci [1 ]
Goktas, Zeynep [2 ]
Uzman, Metin [1 ]
Nazligul, Yasar [1 ]
机构
[1] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Gastroenterol, Sanatoryum Caddesi Ardahan Sokak D 25, TR-06280 Ankara, Turkey
[2] Hacettepe Univ, Kecloren Training & Res Hosp, Dept Nutr & Dietet, Fac Hlth Sci, Ankara, Turkey
关键词
Helicobacter pylori infection; Bismuth-containing quadruple therapy; Levofloxacin-containing triple therapy; Eradication rate; RESCUE REGIMENS; EFFICACY; CLARITHROMYCIN; RESISTANCE; METAANALYSIS; INFECTION;
D O I
10.1159/000484930
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to compare the efficacy and safety of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth-containing quadruple therapy as a firstline regimen for the eradication of Helicobacter pylori. Methods: A total of 329 patients with H. pylori infection were randomly divided into 3 groups to receive one of the following regimens: (a) levofloxacin-containing bismuth quadruple therapy RBAL (rabeprazole 20 mg, b.i.d., bismuth subsalicylate 562 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily), (b) standard bismuth quadruple therapy, RBMT (rabeprazole 20 mg, b.i.d, subsalicylate 562 mg, b.i.d., metronidazole 500 mg, t.i.d, tetracycline 500 mg, q.i.d), or (c) levo-floxacin-containing triple therapy, RAL (rabeprazole 20 mg, b.i.d., amoxicillin 1 g, b.i.d, levofloxacin 500 mg, once daily). The primary outcome was the eradication rate in the intention-to-treat (ITT) and per protocol (PP) analysis. Results: The eradication rates of the above 3 groups using ITT analysis were RBAL 83.8%, RBMT 88.3%, and RAL 74.8% compared with 91.2, 92.5, and 79.2%, respectively, using PP analysis. The eradication rate using RBMT was significantly higher than that of RAL (p = 0.029 in ITT analysis and p = 0.017 in PP analysis). Several side effects occurred in 156 patients (54.1%) in the RBAL group, 215 (52.3%) in the RBMT group, and 56 (26.2%) in the RAL group (p > 0.05, RBAL vs. RBMT; p < 0.001, RBMT vs. RAL; p < 0.001, RBAL vs. RAL). Conclusion: All bismuth-containing quadruple therapies had acceptable eradication rates, but levofloxacin-containing triple therapy was not as good as quadruple therapies. Hence, quadruple therapies should be considered the preferred first-line therapy for H. pylori infections. (C) 2017 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:523 / 529
页数:7
相关论文
共 29 条
[1]   ACG Clinical Guideline: Treatment of Helicobacter pylori Infection [J].
Chey, William D. ;
Leontiadis, Grigorios I. ;
Howden, Colin W. ;
Moss, Steven F. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 (02) :212-239
[2]   Helicobacter pylori in Health and Disease [J].
Cover, Timothy L. ;
Blaser, Martin J. .
GASTROENTEROLOGY, 2009, 136 (06) :1863-1873
[3]   Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection [J].
Federico, Alessandro ;
Nardone, Gerardo ;
Gravina, Antonietta G. ;
Iovene, Maria Rosaria ;
Miranda, Agnese ;
Compare, Debora ;
Pilloni, Paola A. ;
Rocco, Alba ;
Ricciardiello, Luigi ;
Marmo, Riccardo ;
Loguercio, Carmelina ;
Romano, Marco .
GASTROENTEROLOGY, 2012, 143 (01) :55-U563
[4]   Meta-analysis:: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori [J].
Fischbach, L. ;
Evans, E. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) :343-357
[5]   First-line triple therapy with levofloxacin for Helicobacter pylori eradication [J].
Gisbert, J. P. ;
Fernandez-Bermejo, M. ;
Molina-Infante, J. ;
Perez-Gallardo, B. ;
Prieto-Bermejo, A.-B. ;
Mateos-Rodriguez, J.-M. ;
Robledo-Andres, P. ;
Gonzalez-Garcia, G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (03) :495-500
[6]   Systematic review and meta-analysis:: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure [J].
Gisbert, JP ;
De La Morena, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (01) :35-44
[7]   Helicobacter pylori: The Past, Present, and Future in Management [J].
Kamboj, Amrit K. ;
Cotter, Thomas G. ;
Oxentenko, Amy S. .
MAYO CLINIC PROCEEDINGS, 2017, 92 (04) :599-604
[8]   Inefficacy of Triple Therapy and Comparison of Two Different Bismuth-containing Quadruple Regimens as a Firstline Treatment Option for Helicobacter pylori [J].
Kekilli, Murat ;
Onal, Ibrahim K. ;
Ocal, Serkan ;
Dogan, Zeynal ;
Tanoglu, Alpaslan .
SAUDI JOURNAL OF GASTROENTEROLOGY, 2016, 22 (05) :366-369
[9]   Current and Potential Applications of Bismuth-Based Drugs [J].
Keogan, Donal M. ;
Griffith, Darren M. .
MOLECULES, 2014, 19 (09) :15258-15297
[10]   Prevalence of Primary Antimicrobial Resistance of H-pylori in Turkey: A Systematic Review [J].
Kocazeybek, Bekir ;
Tokman, Hrisi Bahar .
HELICOBACTER, 2016, 21 (04) :251-260